255 related articles for article (PubMed ID: 20880396)
1. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Rossi A; Pergola C; Koeberle A; Hoffmann M; Dehm F; Bramanti P; Cuzzocrea S; Werz O; Sautebin L
Br J Pharmacol; 2010 Oct; 161(3):555-70. PubMed ID: 20880396
[TBL] [Abstract][Full Text] [Related]
2. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
3. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Collin M; Rossi A; Cuzzocrea S; Patel NS; Di Paola R; Hadley J; Collino M; Sautebin L; Thiemermann C
J Leukoc Biol; 2004 Nov; 76(5):961-70. PubMed ID: 15328337
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
[TBL] [Abstract][Full Text] [Related]
5. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A
Joshi V; Venkatesha SH; Ramakrishnan C; Nanjaraj Urs AN; Hiremath V; Moudgil KD; Velmurugan D; Vishwanath BS
Pharmacol Res; 2016 Nov; 113(Pt A):265-275. PubMed ID: 27597642
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
Rao TS; Currie JL; Shaffer AF; Isakson PC
Life Sci; 1993; 53(9):PL147-52. PubMed ID: 8394967
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
8. Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Genovese T; Rossi A; Mazzon E; Di Paola R; Muià C; Caminiti R; Bramanti P; Sautebin L; Cuzzocrea S
Br J Pharmacol; 2008 Feb; 153(3):568-82. PubMed ID: 18059327
[TBL] [Abstract][Full Text] [Related]
9. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2-dependent generation of 8-epiprostaglandin F2alpha by lipopolysaccharide-activated J774 macrophages.
Sautebin L; Ianaro A; Rombolà L; Ialenti A; Sala A; Di Rosa M
Inflamm Res; 1999 Sep; 48(9):503-8. PubMed ID: 10522806
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4).
Li X; Yu Y; Funk CD
FASEB J; 2013 Dec; 27(12):4987-97. PubMed ID: 24005906
[TBL] [Abstract][Full Text] [Related]
13. Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors.
Glaser KB; Sung A; Bauer J; Weichman BM
Biochem Pharmacol; 1993 Feb; 45(3):711-21. PubMed ID: 8442770
[TBL] [Abstract][Full Text] [Related]
14. Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity.
Yong EC; Chi EY; Henderson WR
J Exp Med; 1994 Nov; 180(5):1637-48. PubMed ID: 7964451
[TBL] [Abstract][Full Text] [Related]
15. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids.
Swierkosz TA; Mitchell JA; Warner TD; Botting RM; Vane JR
Br J Pharmacol; 1995 Apr; 114(7):1335-42. PubMed ID: 7541688
[TBL] [Abstract][Full Text] [Related]
16. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
Koeberle A; Rossi A; Zettl H; Pergola C; Dehm F; Bauer J; Greiner C; Reckel S; Hoernig C; Northoff H; Bernhard F; Dötsch V; Sautebin L; Schubert-Zsilavecz M; Werz O
J Pharmacol Exp Ther; 2010 Mar; 332(3):840-8. PubMed ID: 19934399
[TBL] [Abstract][Full Text] [Related]
17. Role of Ca(2+)-independent phospholipase A(2) and cyclooxygenase/lipoxygenase pathways in the nitric oxide production by murine macrophages stimulated by lipopolysaccharides.
Vivancos M; Moreno JJ
Nitric Oxide; 2002 May; 6(3):255-62. PubMed ID: 12009843
[TBL] [Abstract][Full Text] [Related]
18. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
19. Prolonged lipopolysaccharide inhibits leukotriene synthesis in peritoneal macrophages: mediation by nitric oxide and prostaglandins.
Brock TG; McNish RW; Mancuso P; Coffey MJ; Peters-Golden M
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):131-45. PubMed ID: 14518557
[TBL] [Abstract][Full Text] [Related]
20. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
Kwak HJ; Park KM; Choi HE; Lim HJ; Park JH; Park HY
Cell Signal; 2010 Jan; 22(1):80-7. PubMed ID: 19781629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
